Release of the 2024 National Survey on Drug Use and Health: Leveraging the Latest Substance Use and Mental Health Data to Make America Healthy Again
Impact on your practice
This data release is important for understanding population trends but doesn't directly change practice operations. It may influence future funding allocations and policy priorities that affect therapists indirectly.
Key facts
2024 National Survey on Drug Use and Health released with latest epidemiological data
Provides updated prevalence rates for mental health and substance use conditions
Data informs federal funding priorities and policy decisions
Therapy Companion analysis
The 2024 NSDUH data signals a significant shift in your patient population and referral patterns over the next 12-24 months. Nearly 50 million Americans (16.8% of the population) meet diagnostic criteria for substance use disorder, while 61.5 million adults report any mental illness—these are your core market demographics. However, the treatment gap remains severe: only 19.3% of people needing substance use treatment actually receive it, while 52.1% of adults with any mental illness and 70.8% with serious mental illness do access mental health treatment. This means your practice will likely see increased demand for mental health services, particularly from younger adults (18-25 year-olds show the highest rates of anxiety, depression, and suicidal ideation). The data also reveals troubling upward trends in illicit drug use, marijuana use disorder, and hallucinogen use from 2021-2024, suggesting your caseload will increasingly include polysubstance use presentations requiring integrated treatment approaches. If you're not already equipped to screen for and address substance use alongside mental health conditions, you're missing a significant portion of your addressable market and potentially underserving existing clients. The adolescent mental health crisis is particularly acute: 18.8% of teens have moderate-to-severe anxiety, 15.4% have major depressive episodes, and 10.1% report serious suicidal thoughts. This data will directly influence insurance companies' prior authorization criteria, funding allocations to community mental health centers, and state Medicaid expansion decisions—all of which affect your reimbursement rates and patient volume within the next fiscal year.
Background
SAMHSA released this epidemiological snapshot to establish a data-driven foundation for the Trump Administration's 'Making America Healthy Again' (MAHA) agenda. The 2024 NSDUH is the first annual survey since 2020 with four consecutive years of comparable data (2021-2024), allowing trend analysis that was previously impossible. This timing is critical: federal agencies use NSDUH data to justify funding allocations, set policy priorities, and guide state-level implementation of mental health and substance use initiatives. The survey captures 73.6 million Americans reporting past-year illicit drug use, 50 million with substance use disorders, and 61.5 million with any mental illness—populations that directly translate into demand for your services. The emergence of novel synthetic opioids (fentanyl, nitazenes, xylazine) and increasing polysubstance use patterns mean the clinical complexity of your cases is rising, even as the overall prevalence of some traditional substances (tobacco, binge drinking) declines. This data release is being positioned as foundational evidence for reshaping federal mental health and substance use policy, which will cascade into changes in Medicaid reimbursement, grant funding priorities, and insurance coverage mandates within 6-18 months.
What you should do
Audit your current intake and assessment protocols to ensure you're systematically screening for both substance use and mental health conditions. The data shows 16% of Americans have substance use disorders while 23.4% have any mental illness—many clients present with both. If your intake doesn't include validated substance use screening (e.g., AUDIT, DAST-10), add it immediately to capture this comorbidity and justify treatment intensity to insurers.
Review your clinical documentation standards to explicitly address polysubstance use patterns and synthetic opioid exposure. Insurance companies will increasingly require evidence that you've assessed for fentanyl, xylazine, and benzodiazepine use given the epidemiological shift. Document your rationale for session frequency and modality based on NSDUH-informed risk stratification (e.g., young adults 18-25 show highest suicide risk and warrant more intensive monitoring).
Develop or strengthen referral partnerships with substance use disorder treatment providers and psychiatric prescribers. With only 19.3% of people needing substance use treatment actually receiving it, you'll encounter significant unmet need. Having warm handoff relationships with MAT providers, intensive outpatient programs, and psychiatrists will improve your treatment outcomes and reduce liability exposure when you identify untreated substance use disorders.
Prepare for increased demand from adolescents and young adults (ages 12-25) by Q3 2025. The data shows 33.2% of 18-25 year-olds have any mental illness, 14.5% have moderate-to-severe anxiety, and 15.9% have major depressive episodes. If you're not currently accepting adolescent clients or have limited pediatric capacity, consider expanding or establishing referral networks, as insurance companies and state Medicaid programs will prioritize funding for youth mental health services based on this data.
Monitor federal and state policy announcements over the next 6 months for changes to Medicaid reimbursement rates, prior authorization requirements, and substance use disorder coverage mandates. SAMHSA will use this data to justify funding shifts and policy changes. Subscribe to your state's Medicaid agency updates and your professional association's policy alerts to stay ahead of changes that will affect your revenue and operational requirements.
Notable excerpts
"Nearly 50 million Americans, 16.8% of people 12 years or older, met diagnostic criteria for a substance use disorder in the past year." This establishes the scale of untreated substance use in your potential patient population.
"In 2024, approximately 1 in 5 people (19.3%) who needed substance use treatment, actually received treatment in the past year." This 80% treatment gap underscores the market opportunity and clinical need for integrated mental health and substance use services.
"Among adults 18 years or older in 2024, 5.5% (14.3 million) reported serious thoughts of suicide in the past year, 1.8% (4.6 million) made a suicide plan, and 0.8% (2.2 million) attempted suicide." This suicide risk data will inform insurance prior authorization criteria and your documentation requirements for high-risk clients.
"Among adolescents aged 12 to 17, 15.4% (3.8 million) had a past year MDE and 11.3% (2.8 million) had a past year MDE with severe impairment in 2024." This adolescent depression prevalence will drive state and federal funding priorities toward youth mental health services.
View full source text
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
STAT+: Trump administration quietly picks Timothy Westlake to lead mental health agency
SAMHSA leadership directly impacts federal funding streams, clinical guidance, and regulatory priorities that affect therapists nationwide. Westlake's background in addiction policy signals potential shifts in how SAMHSA allocates resources and develops clinical standards.
[OK] HB1911: Mental health; definitions; 988 Suicide and Crisis Lifeline System; administrative structure; evaluation; workforce retention; trust fund; telecommunication fee; maximization of federal funding; effective date.
This bill addresses the operational backbone of Oklahoma's 988 system with emphasis on workforce stability and federal funding leverage. For therapists, stable 988 infrastructure and workforce retention means more reliable crisis response for clients and potential partnership opportunities. The federal funding maximization language suggests the state is actively pursuing SAMHSA grants and other federal resources.
[OK] HB4092: 988 Mental Health Lifeline; terms; Department of Mental Health and Substance Abuse Services; suicide prevention and crisis service activities; performance and clinical standards; promulgation of rules; 988 Lifeline Revolving Fund; purpose; funding; enforcement; effective date.
While this bill primarily affects crisis centers and 988 infrastructure rather than direct therapy practice, it signals state investment in crisis services that may create referral pathways and reduce emergency department burden for therapists' clients. The funding mechanism and performance standards could influence how crisis services coordinate with outpatient mental health providers.
HHS clears 2 peer support programs for federal foster care funding
This expands federal funding pathways for peer support-based interventions in child welfare and family services. Therapists working in family-based treatment, substance use, or child welfare may see increased referrals or partnership opportunities as states adopt these programs, though direct reimbursement impact is limited.